RxDoctor Payments Data

Fnu Asad-Ur-Rahman, MD

Gastroenterology · Weston, FLNPI 1083023998

Payments from drug & device makers

$83,944in general payments, 2019–2025

Across 273 payments — averaging $307.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$81K
  • Johnson & Johnson$765
  • Takeda Pharmaceuticals U.S.A., Inc.$705
  • Janssen Scientific Affairs, LLC$216
  • Sanofi$185
  • Bristol Myers Squibb$156
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$65,98179%
  • Travel & lodging$10,97113%
  • Food & beverage$6,8288%
  • Education$1640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,944 in reported general payments places this provider in the 85th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$60,561
Medicare patients
239
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab26$746,129
Skyrizi On-BodyRisankizumab-Rzaa13$251,323
OcalivaObeticholic Acid11$104,562
RemicadeInfliximab12$62,816
XifaxanRifaximin18$41,288
LinzessLinaclotide35$40,301
Ursodiol32$6,224
Octreotide Acetate12$6,116
Mesalamine18$4,043
Colestipol Hcl20$2,918
Omeprazole93$1,887
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg59$1,192
Pantoprazole Sodium25$972
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$874
Azathioprine12$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$765$808,94538 claims
Intercept Pharmaceuticals, Inc.Ocaliva$125$104,56211 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$142$41,28818 claims
AbbVieLinzess$80,767$40,30135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →